公司概况与战略定位 - Oncotelic Therapeutics Inc 是一家临床阶段生物制药公司 专注于肿瘤学和免疫疗法产品的开发 [4] - 公司使命是利用创新的后期治疗候选药物 解决高未满足需求的癌症和罕见儿科疾病 [4] - 公司在首席执行官Dr Vuong Trieu的领导下 利用人工智能、纳米医学和新型临床模型重塑生物技术领域 [3] 研发实力与知识产权 - 公司拥有强大的知识产权基础 拥有超过500项专利申请和75项已授权专利 [3] - 公司首席执行官Dr Vuong Trieu个人提交了超过150项专利申请并持有39项美国授权专利 [4] - 公司正在建立一个旨在改变癌症和罕见疾病治疗的突破性产品组合 [3] 业务模式与合作伙伴关系 - 除了直接拥有和开发的药物管线 公司还通过合资企业进行药物候选物的授权和共同开发 [4] - 公司目前拥有GMP Bio合资企业45%的股份 该企业在首席执行官领导下推进其自身的药物候选管线 [4] - GMP Bio的管线进一步补充和加强了公司在肿瘤学和罕见疾病治疗领域的战略地位 [4] 行业背景与市场机遇 - RNA基础疗法、免疫疗法和靶向治疗领域的创新是迫切需要的 [2] - 胶质母细胞瘤和胰腺癌等侵袭性癌症以及罕见儿科疾病每年导致大量死亡 存在巨大的未满足医疗需求 [2] - 公司与其他领先的创新者一起 致力于改变癌症和罕见疾病的治疗格局 [3]

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 18, 2024. Registration No. 333-276467 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) | Delaware | 2834 | 81-1065054 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorp ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 17, 2024. Registration No. 333-276467 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) | Delaware 2834 | | 81-1065054 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorp ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 22, 2023. Registration No. 333-274251 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 81-1065054 (Primary Standard Industrial Classification Code Number) ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 8, 2023. Registration No. 333-274251 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) AMENDMENT NO. 1 TO Delaware 2834 81-1065054 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) (Primary Standard Ind ...